- How You Can Help Prevent Suicide During the COVID-19 Pandemic
- ‘Silent’ COVID-19 Produces as Much Virus as in Patients With Symptoms: Study
- Immune System Clues to Why COVID Is Easier on Kids
- Is Shock Therapy Making a Comeback Against Bipolar Disorder?
- Conspiracy Theories Are Helping Fuel Rejection of Masks, Vaccines
- U.S. Coronavirus Cases Top 7 Million
- Health Highlights: Sept. 25, 2020
- After COVID-19 Exposure, When Can Young Athletes Resume Play?
- Kids Who Need Steroids Face Risk of Diabetes, Other Ills
- COVID Bites: Cracked Teeth Another Coronavirus Scourge
Sprix Approved for Moderate-to-Severe Pain
MONDAY, May 17Roxro Pharma’s Sprix (ketorolac tromethamine) nasal spray has been approved by the U.S. Food and Drug Administration for the short-term treatment of moderate to moderately severe pain, the manufacturer said Monday in a news release.
The nasal spray contains the non-steroidal anti-inflammatory drug (NSAID) ketorolac. The non-narcotic medication minimizes the chances for abuse and eliminates side effects associated with narcotic pain relievers, the drug maker said.
The drug should not be used for longer than five days. Potential side effects may include peptic ulcers or gastrointestinal bleeding, and the drug shouldn’t be used in people who already have these conditions, a high risk of bleeding, or advanced renal failure, the company said.
Roxro is based in Menlo Park, Calif.
More information
The U.S. National Library of Medicine has more about pain relievers.
Source: HealthDay
